C1q and TNF related 9Genealiases: AQL1 · C1QTNF9A · CTRP9
Q-omics provides the consensus-scored C1QTNF9 profile across patient tissues and cancer cell-line models. C1QTNF9 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C1QTNF9 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, C1QTNF9 RNA expression shows 10,733 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, COAD, and THYM as cancer lineages where C1QTNF9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1QTNF9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1QTNF9 survival associations across molecular data types. C1QTNF9 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1QTNF9 RNA expression–survival associations across cancer types. High C1QTNF9 expression shows unfavorable associations in UVM and LGG, but favorable associations in BRCA, LUAD, KIRC and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for C1QTNF9 RNA expression.
This table summarizes C1QTNF9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for C1QTNF9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1QTNF9 shows lower tumor expression in COAD, BLCA, THCA, KICH, LUSC and READ. The COAD box plot shows higher C1QTNF9 RNA expression in normal versus tumor tissue (log2 FC = −0.701, t-test p < 0.001).
This table shows molecular features associated with C1QTNF9 in patient tissues and cancer cell lines. In patient samples, C1QTNF9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C1QTNF9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SKIN.
